- Home
- LTRN vs CMMB Comparison
LTRN vs CMMB Comparison
Compare LTRN & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LTRN | CMMB |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 8.4M |
| IPO Year | 2020 | 2023 |
Fundamental Metrics
Financial Performance| Metric | LTRN | CMMB |
|---|---|---|
| Price | $0.65 | $1.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $17.50 | $15.00 |
| AVG Volume (30 Days) | ★ 263.4K | 33.6K |
| Earning Date | 11-12-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.65 | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $28.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.59 | $0.92 |
| 52 Week High | $4.34 | $3.07 |
Technical Indicators
Market Signals| Indicator | LTRN | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 31.02 | 30.87 |
| Support Level | $0.59 | $1.05 |
| Resistance Level | $1.96 | $1.91 |
| Average True Range (ATR) | 0.09 | 0.12 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 24.02 | 34.68 |
Price Performance
Historical ComparisonAbout LTRN Lantern Pharma Inc.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.